Angiotensin.

The release and fate of vaso-active hormones in the circulation. Br J Pharmacol (1969) 7.90

THE EFFECT OF ANGIOTENSIN II ON THE BLOOD PRESSURE IN HUMANS WITH HYPERTENSIVE DISEASE. J Clin Invest (1964) 1.89

Humoral stimulation of adrenal cortical secretion. J Clin Invest (1962) 1.79

PLASMA RENIN CONCENTRATION IN HUMAN HYPERTENSION. 1. RELATIONSHIP BETWEEN RENIN, SODIUM, AND POTASSIUM. Br Med J (1965) 1.76

The effects of alteration of blood-volume on the concentration of circulating angiotensin in anaesthetized dogs. J Physiol (1966) 1.66

The estimation of renin in plasma by an enzyme kinetic technique. Biochem J (1964) 1.56

Central components of the renin-angiotensin system. Br J Pharmacol (1971) 1.45

Renin and angiotensin. A survey of some aspects. Postgrad Med J (1966) 1.45

The effect on drinking of peptide precursors and of shorter chain peptide fragments of angiotensin II injected into the rat's diencephalon. J Physiol (1971) 1.29

The purification and partial characterization of several forms of hog renin substrate. J Exp Med (1963) 1.26

CHANGES IN THE EXTRACELLULAR FLUID VOLUME AND CARDIAC OUTPUT DURING THE DEVELOPMENT OF EXPERIMENTAL RENAL HYPERTENSION. Can Med Assoc J (1964) 1.25

Angiotensin II rapidly increases phosphatidate-phosphoinositide synthesis and phosphoinositide hydrolysis and mobilizes intracellular calcium in cultured arterial muscle cells. Proc Natl Acad Sci U S A (1984) 1.14

Purification of an angiotensin II binding protein by using antibodies to a peptide encoded by angiotensin II complementary RNA. Proc Natl Acad Sci U S A (1988) 1.04

REDUCED VASCULAR RESPONSE TO ANGIOTENSIN II IN SECONDARY HYPERALDOSTERONISM. J Clin Invest (1963) 1.03

THE RELATIONSHIP OF ANGIOTENSIN TO RENAL HYPERTENSION. Can Med Assoc J (1964) 1.03

Salt craving: the psychobiology of pathogenic sodium intake. Physiol Behav (2008) 1.02

Increased susceptibility to pyelonephritis during acute hypertension by angiotensin II and norepinephrine. J Clin Invest (1963) 1.01

Renin substrate in granules from rat kidney cortex. Biochem J (1976) 0.99

PATTERNS OF PRESSOR RESPONSE TO NOXIOUS STIMULI IN NORMAL, HYPERTENSIVE, AND DIABETIC SUBJECTS. J Clin Invest (1963) 0.96

The effects of somatostatin and metiamide on tachyphylaxis of pentagastrin stimulated gastric acid and pepsin secretion in the conscious cat. J Physiol (1977) 0.95

Isolation and amino acid composition of human angiotensin I. Biochem J (1967) 0.93

LOSS OF THE RENAL VASOCONSTRICTOR ACTIVITY OF ANGIOTENSIN II DURING RENAL ISCHEMIA. J Clin Invest (1964) 0.92

The relationship of the renal vascular activity of angiotensin II to the autonomic nervous system. J Clin Invest (1965) 0.92

THE CHEMISTRY OF RENIN SUBSTRATE. Can Med Assoc J (1964) 0.90

Fine structure of normal human juxtaglomerular cells. I. General structure and intercellular relationships. Am J Pathol (1966) 0.88

Angiotensin increases Na+ entry and Na+/K+ pump activity in cultures of smooth muscle from rat aorta. Proc Natl Acad Sci U S A (1982) 0.86

The kidneys and arterial pressure in immature and adult rabbits. J Physiol (1969) 0.86

Plasma angiotensinase activity in patients with hypertension and edema. J Clin Invest (1963) 0.85

Characterization of angiotensin receptors in vascular and intestinal smooth muscles. Br J Pharmacol (1973) 0.84

[Vasoactive substances belonging to the body and pharmacologic agents with peripheral point of application]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd (1967) 0.83

Subcellular localization of renin and kininogenase in the rat kidney. Br J Pharmacol (1970) 0.81

Isolation and identification of a pepsitensin. Biochem J (1965) 0.80

The progressive pressor response to angiotensin in the rabbit. J Physiol (1967) 0.79

THE HORMONAL CONTROL OF BODY SODIUM. Postgrad Med J (1964) 0.78

Biosynthetic pathways and the role of the MAS receptor in the effects of Angiotensin-(1-7) in smooth muscles. Int J Hypertens (2011) 0.76

Pressor agents. Calif Med (1967) 0.75

Renal vascular hypertension. Calif Med (1961) 0.75

Recent advances in the treatment of hypertension. Calif Med (1966) 0.75

Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol (1953) 3.48

Electrophoretic and ultracentrifugal analysis of serum lipoproteins of normal, nephrotic and hypertensive persons. Circulation (1953) 2.97

A new, potent antihypertensive drug: preliminary study of [2-(octahydro-1-azocinyl)-ethyl]-guanidine sulfate (guanethidine). J Am Med Assoc (1959) 2.83

Ultracentrifuge lipoprotein pattern of serum of normal, hypertensive and hypothyroid animals. Am J Physiol (1952) 2.69

The vascular action of natural serotonin, 5- and 7-hydroxytryptamine and tryptamine. J Pharmacol Exp Ther (1952) 2.63

The variable arterial pressure response to serotonin in laboratory animals and man. Circ Res (1953) 2.57

Urinary formaldehydogenic corticoids: normal values and observations in hypertension. J Lab Clin Med (1950) 2.33

Mechanisms, diagnosis and treatment of hypertension of renal vascular origin. Ann Intern Med (1959) 2.31

Cardiovascular actions of sodium nitroprusside in animals and hypertensive patients. Circulation (1955) 2.15

Significance of cryoprofibrin in fibrinogen-fibrin conversion. J Exp Med (1962) 2.15

Baroceptor function in chronic renal hypertension. Circ Res (1956) 2.12

Effect of triton on lipoprotein lipase of rat plasma. Am J Physiol (1957) 1.95

The effectiveness of long-term treatment of malignant hypertension. Circulation (1958) 1.90

Serotonin (5-hydroxytryptamine); the last four years. Physiol Rev (1958) 1.89

Serotonin (5-hydroxytryptamine). Physiol Rev (1954) 1.80

Angiotensinase with a high degree of specificity in plasma and red cells. Science (1963) 1.76

Ability of vasoconstrictor drugs to cause adrenal medullary discharge after "sensitization" by ganglion stimulating agents. Circ Res (1961) 1.75

Separation and characterization of the protein moiety of human alpha1-lipoprotein. Arch Biochem Biophys (1958) 1.69

Peripheral vasomotor effects of adrenaline and noradrenaline acting upon the isolated perfused central nervous system. Circulation (1951) 1.67

Atherosclerosis; an introduction. Circulation (1954) 1.67

Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem (1948) 1.66

CONTROL OF RENIN SECRETION. Circ Res (1964) 1.60

Plasma lipids and proteins and their relationship to coronary disease among Navajo Indians. Circulation (1956) 1.59

A hormonal neurogenic vasopressor mechanism. AMA Arch Intern Med (1951) 1.59

Studies on the protective power of adrenal extract and steroids against bacterial toxins in adrenalectomized rats. Ann N Y Acad Sci (1949) 1.58

Serum lipid levels in normal persons; findings of a cooperative study of lipoproteins and atherosclerosis. Circulation (1957) 1.48

Induced hypercholesterolemia and atherogenesis. Circulation (1952) 1.43

Relationships among intravascular volume, total body sodium, arterial pressure, and vasomotor tone. Circ Res (1961) 1.42

Use of fat-modified foods for serum cholesterol reduction. JAMA (1963) 1.41

A mechanism of chlorothiazide-enhanced effectiveness of antihypertensive ganglioplegic drugs. Circulation (1959) 1.40

RENAL BAROCEPTOR CONTROL OF RENIN SECRETION. Science (1963) 1.39

The metabolism of serotonin (5-hydroxytryptamine). J Biol Chem (1959) 1.36

Augmentation of vasoactive substances by tetraethylammonium chloride. Circulation (1950) 1.36

Argentaffinoma as endocrine tumour. Lancet (1955) 1.35

The prolonged treatment of hypertension with guanethidine. JAMA (1961) 1.34

Accelerated hypertensive vascular disease from saline and renin in nephrectomized dogs. AMA Arch Pathol (1953) 1.28

Effects of bradykinin and angiotensin on smooth muscle. Ann N Y Acad Sci (1963) 1.26

Hypertension due to renal compression resulting from subcapsular hematoma. J Urol (1955) 1.25

Mecamylamine in treatment of hypertensive disease; observations on an unusual neuromuscular complication. J Am Med Assoc (1956) 1.25

New metabolites of serotonin in carcinoid urine. Science (1958) 1.25

Studies on the antigenicity of beta- and alpha-lipoproteins of human serum. J Exp Med (1958) 1.25

Serotonin metabolism in carcinoid syndrome with metastatic bronchial adenoma. J Am Med Assoc (1959) 1.24

Antidiuresis and other renal responses to piperoxan in pheochromocytoma. Circulation (1956) 1.24

The peripheral cardiovascular actions of guanethidine in dogs. J Pharmacol Exp Ther (1961) 1.23

Enhanced effectiveness of ganglion-blocking agents in hypertensive patients during administration of a saluretic agent (chlorothiazide). Lancet (1957) 1.23

A vasopressor lipid in incubated plasma. Am J Physiol (1960) 1.22

Pharmacologic aspects of synthetic angiotonin. Circ Res (1957) 1.21

Modification of vascular response to serotonin by drugs. Am J Physiol (1953) 1.20

Atherosclerosis and the fat content of the diet. Circulation (1957) 1.16

Experimental production of a syndrome resembling toxemia of pregnancy. J Lab Clin Med (1951) 1.16

Lithium poisoning from the use of salt substitutes. J Am Med Assoc (1949) 1.15

Further evaluation of hydralazine in treatment of hypertensive disease. AMA Arch Intern Med (1954) 1.14

Angiotensin II: its metabolic fate. Science (1962) 1.14

Synthesis and pharmacology of the octapeptide angiotonin. Science (1957) 1.12

Blood pressure in the unanesthetized rat. II. Spontaneous variations and effect of heat. Circulation (1951) 1.12

The influence of respiratory gas mixtures on arterial pressure and vascular reactivity in normal and hypertensive dogs. Circulation (1951) 1.12

Ability of serotonin and norepinephrine to mimic the central effects of reserpine on vasomotor activity. Circ Res (1960) 1.12

DISTRIBUTION AND METABOLIC FATE OF ANGIOTENSIN II AND VARIOUS DERIVATIVES. Can Med Assoc J (1964) 1.12

The purification of hog renin substrate. J Biol Chem (1954) 1.11

AN UNUSUAL SERUM LIPOPROTEIN-GLOBULIN COMPLEX IN A PATIENT WITH HYPERLIPEMIA. Am J Med (1965) 1.11

Renal function in primary aldosteronism. J Clin Invest (1956) 1.10

Renal hypertension. N Engl J Med (1959) 1.10

Electrophoretic study of plasma proteins following hepatectomy in dogs. Am J Physiol (1949) 1.07

ANGIOTENSIN IN BLOOD AND LYMPH FOLLOWING REDUCTION IN RENAL ARTERIAL PERFUSION PRESSURE IN DOGS. Circ Res (1963) 1.07

HEMODYNAMIC STUDIES IN NORMOTENSIVE AND RENAL HYPERTENSIVE CHRONIC SPINAL DOGS. Am J Physiol (1964) 1.07

Nature of the hypotensive action of a thiophanium derivative (Ro 2-2222) in dogs. J Pharmacol Exp Ther (1952) 1.05

The effect of venous occlusion on serum cholesterol and total protein concentration-a warning. Circulation (1962) 1.05

Cardiovascular action of 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP); a ganglion stimulating agent useful in the diagnosis of pheochromocytoma. Am J Med (1953) 1.04

Treatment of the nephrotic syndrome with nitrogen mustard. J Lab Clin Med (1950) 1.02

Renal and vascular lesions elicited by renin in rats with desoxycorticosterone hypertension. AMA Arch Pathol (1952) 1.02

Effects of renin and thyroxine in rats treated with corticosteroids and in rats with regenerating adrenals. Endocrinology (1957) 1.01

RENAL BARORECEPTOR CONTROL OF ACUTE RENIN RELEASE IN NORMOTENSIVE, NEPHROGENIC AND NEUROGENIC HYPERTENSIVE DOGS. Circ Res (1964) 1.01

Serotonin or tenure for the pharmacologist. Circulation (1956) 1.00

Effects of serotonin antagonists in normal subjects and patients with carcinoid tumors. Circulation (1957) 0.99

The chemoceptor stimulant action of serotonin in dogs. J Pharmacol Exp Ther (1956) 0.99

Serotonin and its methylated derivatives in human urine. J Biol Chem (1955) 0.99

Arterial hypertension. Pa Med J (1952) 0.98

Treatment of essential and malignant hypertension. J Am Med Assoc (1951) 0.98

A proposed conformation of isoleucyl-5-angiotensin II. Biochim Biophys Acta (1962) 0.97

Current status of bretylium and guanethidine as antihypertensive drugs. Circulation (1960) 0.97

Triton hyperlipemia in dogs. II. Atheroscieross, diffuse lipidosis, and deletion of fat stores produced by prolonged administration of the non-tonic surface-active agent. J Exp Med (1961) 0.97

Controlled observations on the effect of low sodium dietotherapy in essential hypertension. Circulation (1951) 0.96

Cortisone and ACTH in essential hypertension; establishment of renal glycosuria. AMA Arch Intern Med (1951) 0.96

Effects of renin in rats treated with methylandrostenediol. Endocrinology (1955) 0.96

Hemodynamic effects of eledoisin, kallidin II, and bradykinin in unanesthetized dogs. Am J Physiol (1962) 0.96

Mechanism by which serotonin, norepinephrine and reserpine cause central vasomotor inhibition. Circ Res (1960) 0.96

Release of pressor substances from renal grafts originating from rats with renal hypertension. Circ Res (1961) 0.93

The national diet-heart study. An initial report. JAMA (1963) 0.93

Hyposthenuria and other renal effects of hexamethonium in the hydropenic anesthetized dog. J Pharmacol Exp Ther (1956) 0.93

Renal vascular and systemic arterial pressure responses to nervous and chemical stimulation of the kidney. Am J Physiol (1953) 0.93

Angiotonin induction of vascular lesions in desoxycorticosterone-treated rats. Proc Soc Exp Biol Med (1953) 0.93

ACTH in vitro on release of nonesterified fatty acids from adipose tissues of adrenalectomized rats. Proc Soc Exp Biol Med (1959) 0.93

Blood pressure reducing function of the kidney; reduction of renoprival hypertension by kidney perfusion. Am J Physiol (1954) 0.93

Effect of synthetic angiotonin on the carotid sinus. Circ Res (1957) 0.92